Replimune Group, Inc. (NASDAQ:REPL) Director Sells $74,172.08 in Stock

Replimune Group, Inc. (NASDAQ:REPL) Director Robert Coffin sold 11,464 shares of Replimune Group stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $6.47, for a total value of $74,172.08. Following the completion of the transaction, the director now directly owns 1,821,872 shares of the company’s stock, valued at $11,787,511.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Replimune Group Stock Up 6.5 %

Replimune Group stock opened at $5.93 on Thursday. The stock has a 50-day simple moving average of $7.10 and a 200 day simple moving average of $8.17. The company has a quick ratio of 10.72, a current ratio of 10.72 and a debt-to-equity ratio of 0.18. Replimune Group, Inc. has a 12-month low of $5.46 and a 12-month high of $24.81.

Institutional Trading of Replimune Group

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Jacobs Levy Equity Management Inc. acquired a new stake in Replimune Group in the first quarter worth about $1,088,000. Price T Rowe Associates Inc. MD grew its position in shares of Replimune Group by 12.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,548,930 shares of the company’s stock worth $53,505,000 after buying an additional 699,679 shares during the period. Nan Fung Group Holdings Ltd grew its position in shares of Replimune Group by 10.9% during the 1st quarter. Nan Fung Group Holdings Ltd now owns 204,939 shares of the company’s stock worth $1,674,000 after buying an additional 20,200 shares during the period. Clearbridge Investments LLC grew its position in shares of Replimune Group by 2.7% during the 1st quarter. Clearbridge Investments LLC now owns 277,969 shares of the company’s stock worth $2,271,000 after buying an additional 7,274 shares during the period. Finally, Acadian Asset Management LLC acquired a new position in shares of Replimune Group during the 1st quarter worth about $927,000. 92.53% of the stock is currently owned by institutional investors and hedge funds.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.